{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:39:15Z","timestamp":1790807955000,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T00:00:00Z","timestamp":1562889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T00:00:00Z","timestamp":1562889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1038\/s41416-019-0521-7","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T23:03:29Z","timestamp":1562886209000},"page":"312-317","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial"],"prefix":"10.1038","volume":"121","author":[{"given":"Edouard","family":"Auclin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Banzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Van Laethem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamas","family":"Hickish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimery","family":"de Gramont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewi","family":"Vernerey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,12]]},"reference":[{"key":"521_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2018. CA. Cancer J. Clin. 68, 7\u201330 (2018).","journal-title":"CA. Cancer J. Clin."},{"key":"521_CR2","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1093\/annonc\/mdu138","volume":"25","author":"M Malvezzi","year":"2014","unstructured":"Malvezzi, M., Bertuccio, P., Levi, F., La Vecchia, C. & Negri, E. European cancer mortality predictions for the year 2014. Ann. Oncol. 25, 1650\u20131656 (2014).","journal-title":"Ann. Oncol."},{"issue":"Suppl 6","key":"521_CR3","doi-asserted-by":"publisher","first-page":"vi64","DOI":"10.1093\/annonc\/mdt354","volume":"24","author":"R Labianca","year":"2013","unstructured":"Labianca, R., Nordlinger, B., Beretta, G. D., Mosconi, S., Mandal\u00e0, M., Cervantes, A. et al. Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24(Suppl 6), vi64\u201372 (2013).","journal-title":"Ann. Oncol."},{"key":"521_CR4","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andr\u00e9","year":"2004","unstructured":"Andr\u00e9, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T. et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 350, 2343\u20132351 (2004).","journal-title":"N. Engl. J. Med."},{"key":"521_CR5","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.1200\/JCO.2015.63.4238","volume":"33","author":"T Andr\u00e9","year":"2015","unstructured":"Andr\u00e9, T., de Gramont, A., Vernerey, D., Chibaudel, B., Bonnetain, F., Tijeras-Raballand, A. et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III Colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J. Clin. Oncol. 33, 4176\u20134187 (2015).","journal-title":"J. Clin. Oncol."},{"key":"521_CR6","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1084\/jem.122.3.467","volume":"122","author":"P Gold","year":"1965","unstructured":"Gold, P. & Freedman, S. O. Specific carcinoembryonic antigens of the human digestive system. J. Exp. Med. 122, 467\u2013481 (1965).","journal-title":"J. Exp. Med."},{"key":"521_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2018.01.112","volume":";94","author":"O Margalit","year":"2018","unstructured":"Margalit, O., Mamtani, R., Yang, Y.-X., Reiss, K. A., Golan, T., Halpern, N. et al. Assessing the prognostic value of carcinoembryonic antigen levels in stage I and II colon cancer. Eur. J. Cancer. 94, 1\u20135 (2018).","journal-title":"Eur. J. Cancer"},{"key":"521_CR8","doi-asserted-by":"crossref","unstructured":"Hothorn, T. & Lausen, B. On the exact distribution of maximally selected rank statistics. Comput. Stat. Data. Anal. 43, 121\u2013137 (2003).","DOI":"10.1016\/S0167-9473(02)00225-6"},{"key":"521_CR9","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/jnci\/djr078","volume":"103","author":"P Thirunavukarasu","year":"2011","unstructured":"Thirunavukarasu, P., Sukumar, S., Sathaiah, M., Mahan, M., Pragatheeshwar, K. D., Pingpank, J. F. et al. C-stage in colon cancer: implications of carcinoembryonic antigen biomarker in staging, prognosis, and management. J. Natl. Cancer. Inst. 103, 689\u2013697 (2011).","journal-title":"J. Natl. Cancer. Inst."},{"key":"521_CR10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jamaoncol.2017.4420","volume":"4","author":"T Konishi","year":"2018","unstructured":"Konishi, T., Shimada, Y., Hsu, M., Tufts, L., Jimenez-Rodriguez, R., Cercek, A. et al. Association of preoperative and postoperative serum carcinoembryonic antigen and colon cancer outcome. JAMA Oncol. 4, 309\u2013315 (2018).","journal-title":"JAMA Oncol."},{"key":"521_CR11","doi-asserted-by":"publisher","first-page":"4512","DOI":"10.1200\/JCO.2012.47.3116","volume":"31","author":"G Yothers","year":"2013","unstructured":"Yothers, G., O\u2019Connell, M. J., Lee, M., Lopatin, M., Clark-Langone, K. M., Millward, C. et al. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU\/LV) and FU\/LV plus oxaliplatin. J. Clin. Oncol. 31, 4512\u20134519 (2013).","journal-title":"J. Clin. Oncol."},{"key":"521_CR12","doi-asserted-by":"publisher","first-page":"e0171991","DOI":"10.1371\/journal.pone.0171991","volume":"12","author":"G Fan","year":"2017","unstructured":"Fan, G., Zhang, K., Yang, X., Ding, J., Wang, Z. & Li, J. Prognostic value of circulating tumor DNA in patients with colon cancer: systematic review. PLoS ONE. 12, e0171991 (2017).","journal-title":"PLoS ONE."},{"key":"521_CR13","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/ijc.10526","volume":"100","author":"T Lecomte","year":"2002","unstructured":"Lecomte, T., Berger, A., Zinzindohou\u00e9, F., Micard, S., Landi, B., Blons, H. et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int. J. Cancer 100, 542\u2013548 (2002).","journal-title":"Int. J. Cancer"},{"key":"521_CR14","doi-asserted-by":"publisher","first-page":"346ra92","DOI":"10.1126\/scitranslmed.aaf6219","volume":"8","author":"J Tie","year":"2016","unstructured":"Tie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I. et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci. Transl. Med. 8, 346ra92 (2016).","journal-title":"Sci. Transl. Med."},{"key":"521_CR15","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/bjc.2011.40","volume":"104","author":"C-Y Lu","year":"2011","unstructured":"Lu, C.-Y., Uen, Y.-H., Tsai, H.-L., Chuang, S.-C., Hou, M.-F., Wu, D.-C. et al. Molecular detection of persistent postoperative circulating tumour cells in stages II and III colon cancer patients via multiple blood sampling: prognostic significance of detection for early relapse. Br. J. Cancer 104, 1178\u20131184 (2011).","journal-title":"Br. J. Cancer"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0521-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0521-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0521-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:05:22Z","timestamp":1684616722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-019-0521-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,12]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["521"],"URL":"https:\/\/doi.org\/10.1038\/s41416-019-0521-7","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,12]]},"assertion":[{"value":"5 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Thierry Andr\u00e9: Honoraria\u2014AMGEN; Bayer; Bristol-Myers Squibb; PRMA Consulting; Roche\/Genentech; Sanofi; SERVIER; Xbiotech. Consulting or Advisory Role\u2014Amgen; Bayer; Bristol-Myers Squibb; Guardant Health; HalioDX; MSD Oncology; Mundipharma; Roche\/Genentech; SERVIER. Travel, Accommodations, Expenses\u2014Amgen; Bristol-Myers Squibb; MSD Oncology; Roche\/Genentech. Julien Taieb: Consulting or Advisory Role\u2014Amgen; Baxalta; Celgene; Lilly; Merck KGaA; Roche; SERVIER; Sirtex Medical. Speakers\u2019 Bureau\u2014Amgen; Baxalta; Lilly; Merck; Roche\/Genentech; Sanofi; SERVIER. Maria Banzi: Honoraria\u2014Merck; Roche (I). Travel, Accommodations, Expenses\u2014Merck; Pfizer; Roche. Josep Tabernero: Consulting or Advisory Role\u2014Amgen; Boehringer Ingelheim; Celgene; Chugai Pharma; ImClone Systems; Lilly; Merck; Merck Serono; Millennium; Novartis; Roche\/Genentech; Sanofi; Taiho Pharmaceutical. Tamas Hickish: Stock and Other Ownership Interests\u2014Knowledge To Practice. Patents, Royalties, Other Intellectual Property\u2014Bournemouth University (Inst). Travel, Accommodations, Expenses\u2014Philips Healthcare; XBiotech. Aimery De Gramont: Honoraria\u2014Chugai Pharma; Yakult. Dewi Vernerey: Consulting or Advisory Role\u2014HalioDx; Janssen-Cilag; OSE Immunotherapeutics; Prestizia. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The MOSAIC trial was performed in accordance with the Declaration of Helsinki. All patients have given their written consent to be enroled in the MOSAIC trial. Written informed consent was required from all patients and the study was approved by the ethics committees of the participating centres. The use of the data for translational research was approved by the ethic committee of Ile De France (April 29, 2009).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Dataset of the study can be found with the corresponding author.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Note"}}]}}